Piramal Pharma wants to be a $2 billion global firm by 2030, analysts give 5-year plan a thumbs up

Brokerages are optimistic about Piramal Pharma’s growth. Jefferies and Motilal Oswal have given it a ‘buy’ rating and with a target price to ₹260.

Leave a Reply

Your email address will not be published. Required fields are marked *